BioShin Information

View Top Employees from BioShin

About BioShin BioShin Limited, a privately held biopharmaceutical company with offices in Shanghai, is advancing the Biohaven clinical portfolio in the Asia-Pacific region. BioShin holds rights to the Biohaven portfolio for all of the Asia-Pacific Region, including Australia and New Zealand, excluding Japan. BioShin’s neuroinnovation portfolio includes the US FDA-approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and myeloperoxidase inhibition for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven (NYSE: BHVN) is a majority shareholder in BioShin. More information about BioShin is available at www.bioshin.com

Website	http://www.bioshin.com
Employees	16 (2 on RocketReach)
Founded	2018
Technologies	JavaScript , HTML , PHP +9 more (view full list)
Industry	Biotechnology, Drug Discovery, Pharmaceuticals
Keywords	Biopharmaceutical, Biotechnology, Drug Development, Clinical Trials, Pharmaceutical Research, Asia Pacific, Drug Discovery, Therapeutics, Biotechnology Research, Pharmaceutical, Health, Clinical Stage, Life Sciences, Biopharma, Healthcare, Global Health, Medicinal, Research And Development
Competitors	BASF, Givaudan, DSM, Lonza, Corteva Agriscience, My Business, FMC Corporation, Nutraceutical Products Co, Zymergen, Inc., Kappa Bioscience +31 more (view full list)